BREEZULA COVID UPDATE: Filing for Special Protocol Assessment with FDA

    Research/Science 5/30/2020
    The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.
    View this post in the Community →

    Similar Community Posts Join

    6 / 95 results

    Related Research

    6 / 56 results